Article Information
History
- March 19, 2024.
Article Versions
- You are currently viewing Version 1 of this article (March 19, 2024 - 21:24).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Richard A Forshee, PhD1,2,*,
- Elizabeth R Smith, BS2,
- Zhiruo Wan, MS2,
- Kandace L Amend, PhD, MPH3,
- Alex Secora, PhD4,
- Djeneba Audrey Djibo, PhD, MSBME5,
- Kamran Kazemi, BS2,
- Jennifer Song, MA, MURP3,
- Lauren E Parlett, PhD6,
- John D Seeger, DrPH, PharmD3,
- Nandini Selvam, PhD, MPH4,
- Cheryl N McMahill-Walraven, PhD, MSW5,
- Mao Hu, BS2,
- Yoganand Chillarige, MPA2 and
- Steven A Anderson, PhD, MPP1
- 1US Food and Drug Administration, Silver Spring, MD, USA
- 2Acumen LLC, Burlingame, CA, USA
- 3Optum Epidemiology, Boston, MA, USA
- 4IQVIA, Falls Church, VA, USA
- 5CVS Health, Blue Bell, PA, USA
- 6Carelon Research, Inc., Wilmington, DE, USA
- ↵*Corresponding Author:
Richard A. Forshee, PhD Deputy Director, Office of Biostatistics and Pharmacovigilance Center for Biologics Evaluation and Research, U.S. Food & Drug Administration 10903 New Hampshire Ave. Silver Spring, MD 20993, Email: richard.forshee{at}fda.hhs.gov Phone: (240) 402-8631